Ota S, Terano A
Second Department of Internal Medicine, Faculty of Medicine, University of Tokyo, Japan.
J Gastroenterol. 1994 Jul;29 Suppl 7:139-40.
The efficacy of gastric acid suppressive drugs, such as histamine H2-receptor antagonists and H+K+ ATPase inhibitors, in the management of peptic ulcer diseases has been well established. They accelerate the healing of peptic ulcers, and maintenance therapy with these drugs prevents ulcer relapse. However, they do not modulate the natural course of peptic ulcer. Sucralfate, a protective drug, has been shown to be equally effective in ulcer healing and the prevention of ulcer relapse. Some reports suggest that the relapse rate of ulcers treated successfully with sucralfate is less than that seen with histamine H2-receptor antagonists. Sucralfate has a true cytoprotective effect against agents noxious to gastric epithelial cells in monolayer culture. This action might be associated with its therapeutic efficacy in the treatment and prevention of ulcer diseases. The role played by other protective drugs in the management of ulcer diseases is less clear and requires further studies.
胃酸抑制药物,如组胺H2受体拮抗剂和H⁺K⁺ATP酶抑制剂,在消化性溃疡疾病治疗中的疗效已得到充分证实。它们能加速消化性溃疡的愈合,并且用这些药物进行维持治疗可预防溃疡复发。然而,它们并不能调节消化性溃疡的自然病程。硫糖铝,一种保护性药物,已被证明在溃疡愈合和预防溃疡复发方面同样有效。一些报告表明,用硫糖铝成功治疗的溃疡复发率低于用组胺H2受体拮抗剂治疗的溃疡复发率。在单层培养中,硫糖铝对胃上皮细胞有毒性的药物具有真正的细胞保护作用。这一作用可能与其在治疗和预防溃疡疾病中的疗效有关。其他保护性药物在溃疡疾病治疗中的作用尚不清楚,需要进一步研究。